ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
The Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testing.
Dutch VectorY Tx BV has closed one of this yerss largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European partnering event for biotech and pharma. However, many other figures are currently pointing back to 2019.
Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a €11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform.
Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.
Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.
Biotech companies in Scotlands thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme.